|Bid||1.75 x 5000|
|Ask||2.00 x 2000|
|Day's range||1.82 - 1.92|
|52-week range||1.02 - 2.63|
|PE ratio (TTM)||N/A|
|Earnings date||7 Nov. 2017 - 13 Nov. 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.75|
CLEVELAND, Nov. 15, 2017-- Athersys, Inc. announced today that its partner, HEALIOS K.K., has enrolled the first patient in its study in Japan evaluating MultiStem ® cell therapy treatment of patients ...
CLEVELAND, Nov. 08, 2017-- Athersys, Inc. today announced its financial results for the three months ended September 30, 2017.. Highlights of the third quarter of 2017 and recent events include:. Our partner ...
CLEVELAND, Oct. 11, 2017-- Athersys, Inc. today announced that it has entered into a manufacturing services agreement with Nikon CeLL innovation Co., Ltd. for commercial production of its stem cell therapy, ...
CLEVELAND, Oct. 09, 2017-- Athersys, Inc. will release its third quarter 2017 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 8, 2017, and will host a conference call shortly ...
CLEVELAND, Oct. 05, 2017-- Athersys, Inc. announced today that Robert W. Mays, Ph.D., Vice President, Regenerative Medicine and Head of Neuroscience Programs, will present at the annual Partnering Forum ...